Sign In
Buy PCRX
$26.41
-0.560 (-2.08%)
At Close: Jul 31, 2026
Pacira BioSciences' CFO Sold 12,941 Shares for $326,000 Before Its Q1 Earnings Release
08:17am, Friday, 01'st May 2026
Pacira BioSciences, a leader in non-opioid pain management, reported a notable insider sale amid ongoing option exercise activity.
Pacira BioSciences, Inc. (PCRX) Q1 2026 Earnings Call Transcript
11:51pm, Thursday, 30'th Apr 2026
Pacira BioSciences, Inc. (PCRX) Q1 2026 Earnings Call Transcript
Pacira (PCRX) Q1 Earnings Miss Estimates
07:26pm, Thursday, 30'th Apr 2026
Pacira (PCRX) came out with quarterly earnings of $0.6 per share, missing the Zacks Consensus Estimate of $0.61 per share. This compares to earnings of $0.62 per share a year ago.
Pacira BioSciences Reports First Quarter 2026 Financial Results
04:01pm, Thursday, 30'th Apr 2026
-- Total revenue of $177 million, reflecting increase of 5 percent over first quarter 2025 driven by growth across commercial portfolio, including EXPAREL volume growth of 7 percent -- -- Completed en
PharmaCorp to Acquire Eight Pharmacies and Provides Acquisition Pipeline Update
11:04am, Thursday, 30'th Apr 2026
SASKATOON, Saskatchewan, April 30, 2026 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) a Canadian pharmacy acquisition and ownership platform for pharm
PharmaCorp Announces Fourth Quarter and Fiscal Year 2025 Financial Results
08:51pm, Wednesday, 29'th Apr 2026
SASKATOON, Saskatchewan, April 29, 2026 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) a Canadian pharmacy acquisition and ownership platform for phar
Pacira BioSciences Files Definitive Proxy Materials and Mails Letter to Shareholders
04:20pm, Tuesday, 28'th Apr 2026
Urges Stockholders to Vote “FOR” Pacira's Highly Qualified Nominees on the BLUE Proxy Card Today
-- Findings show significant reductions in opioid consumption, healthcare resource utilization, and total medical costs -- -- Findings show significant reductions in opioid consumption, healthcare res
Pacira to Report First Quarter 2026 Financial Results on Thursday April 30, 2026
08:00am, Thursday, 16'th Apr 2026
BRISBANE, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the li
-- Select findings demonstrate that the use of EXPAREL ® (bupivacaine liposome injectable suspension) in outpatient Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA) is associated with l
Pacira BioSciences to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference
08:00am, Wednesday, 08'th Apr 2026
BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the li
-- Studies highlight reduced total cost of care and select healthcare resource utilization outcomes in total knee arthroplasty (TKA) and spinal fusion -- BRISBANE, Calif., March 30, 2026 (GLOBE NEWSWI
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives $30.75 Average Price Target from Analysts
02:07am, Monday, 23'rd Mar 2026
Shares of Pacira BioSciences, Inc. (NASDAQ: PCRX - Get Free Report) have been assigned an average rating of "Hold" from the six research firms that are currently covering the stock, Marketbeat Ratings
DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc.
08:20am, Thursday, 12'th Mar 2026
Pacira's Stock is Down 56% Over the Last Decade and Down 68% Over the Last 5 Years [i] ; Under the Leadership of CEO and Board Member Frank Lee, the Stock Has Fallen 30% [ii] ; The Company's Underperf
Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation
05:02pm, Wednesday, 11'th Mar 2026
-- Issues Statement in Response to DOMA's Nomination of Director Candidates -- -- No Shareholder Action Required at This Time --
